Pre-surgery treatment with chemo, radiation, and two targeted drugs for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of chemotherapy, radiation, and two newer drugs (an immunotherapy and an anti-angiogenesis drug) before surgery can improve outcomes for people with locally advanced rectal cancer. If you qualify, you would receive this treatment for a few months, and then have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal cancer that is locally advanced (grows deeply or has spread to nearby lymph nodes) but hasn't spread to distant organs.
- Your cancer is 'repair-proficient' (a type of cancer cell that doesn't have certain gene mutations).
- You are between 18 and 75 years old.
- You have not received any prior treatment for this rectal cancer (such as chemotherapy, radiation, or surgery).
- You are fit and able to undergo surgery after the trial treatment.
- You do not have severe allergies to the study drugs, active autoimmune diseases, serious heart conditions, or certain infections (like hepatitis B or C or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.